BRPI0213786B8 - peptídeos efetivos no tratamento de tumores e outras condições que requerem a remoção ou destruição de células - Google Patents

peptídeos efetivos no tratamento de tumores e outras condições que requerem a remoção ou destruição de células

Info

Publication number
BRPI0213786B8
BRPI0213786B8 BRPI0213786A BR0213786A BRPI0213786B8 BR PI0213786 B8 BRPI0213786 B8 BR PI0213786B8 BR PI0213786 A BRPI0213786 A BR PI0213786A BR 0213786 A BR0213786 A BR 0213786A BR PI0213786 B8 BRPI0213786 B8 BR PI0213786B8
Authority
BR
Brazil
Prior art keywords
destruction
removal
cells
tumors
require
Prior art date
Application number
BRPI0213786A
Other languages
English (en)
Other versions
BRPI0213786B1 (pt
BR0213786A (pt
Inventor
Gemmell Jack
A Averback Paul
Original Assignee
Nymox Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nymox Corp filed Critical Nymox Corp
Publication of BR0213786A publication Critical patent/BR0213786A/pt
Publication of BRPI0213786B1 publication Critical patent/BRPI0213786B1/pt
Publication of BRPI0213786B8 publication Critical patent/BRPI0213786B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Psychiatry (AREA)
  • General Engineering & Computer Science (AREA)
  • Addiction (AREA)
  • Urology & Nephrology (AREA)
  • Wood Science & Technology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Hematology (AREA)

Abstract

peptídeos efetivos no tratamento de tumores e outras condições que requerem a remoção ou destruição de células. a invenção é direcionada a métodos de tratamento de condições que requerem remoção ou destruição de células danosas ou indesejadas em um paciente, tal como tumores benignos e malignos, utilizando compostos contendo ou baseados em peptídeos compreendendo uma parte da seqüência de amino ácidos de uma proteína em cadeia neural.
BRPI0213786A 2001-11-16 2002-11-18 peptídeos efetivos no tratamento de tumores e outras condições que requerem a remoção ou destruição de células BRPI0213786B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33147701P 2001-11-16 2001-11-16
PCT/CA2002/001757 WO2003044053A2 (en) 2001-11-16 2002-11-18 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells

Publications (3)

Publication Number Publication Date
BR0213786A BR0213786A (pt) 2004-11-09
BRPI0213786B1 BRPI0213786B1 (pt) 2019-01-02
BRPI0213786B8 true BRPI0213786B8 (pt) 2021-05-25

Family

ID=23294135

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0213786A BRPI0213786B8 (pt) 2001-11-16 2002-11-18 peptídeos efetivos no tratamento de tumores e outras condições que requerem a remoção ou destruição de células

Country Status (22)

Country Link
US (5) US7317077B2 (pt)
EP (1) EP1442058B1 (pt)
JP (2) JP4717349B2 (pt)
KR (4) KR101375026B1 (pt)
CN (1) CN100509846C (pt)
AT (1) ATE333467T1 (pt)
AU (1) AU2002342463B2 (pt)
BR (1) BRPI0213786B8 (pt)
CA (1) CA2467053C (pt)
CY (1) CY1107578T1 (pt)
DE (1) DE60213274T2 (pt)
DK (1) DK1442058T3 (pt)
EA (1) EA007203B1 (pt)
ES (1) ES2269775T3 (pt)
IL (2) IL161591A0 (pt)
MX (1) MXPA04004489A (pt)
NO (1) NO332842B1 (pt)
NZ (1) NZ532721A (pt)
PL (1) PL207591B1 (pt)
PT (1) PT1442058E (pt)
WO (1) WO2003044053A2 (pt)
ZA (1) ZA200403624B (pt)

Families Citing this family (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7317077B2 (en) * 2001-11-16 2008-01-08 Nymox Pharmaceutical Corporation Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
DE202004021954U1 (de) 2003-09-12 2013-06-19 Vessix Vascular, Inc. Auswählbare exzentrische Remodellierung und/oder Ablation von atherosklerotischem Material
US20090232866A1 (en) * 2003-10-07 2009-09-17 Mariann Pavone-Gyongyosi Oligopeptides as coating material for medical products
US20050226883A1 (en) * 2004-02-06 2005-10-13 Paul Averback Humanized antibody
US9713730B2 (en) 2004-09-10 2017-07-25 Boston Scientific Scimed, Inc. Apparatus and method for treatment of in-stent restenosis
US8396548B2 (en) 2008-11-14 2013-03-12 Vessix Vascular, Inc. Selective drug delivery in a lumen
CN100427502C (zh) * 2005-06-09 2008-10-22 南京大学 抗肿瘤寡肽及其制备方法和应用
SI1994152T1 (sl) * 2006-02-28 2013-05-31 Nymox Corporation Peptidi uäśinkoviti pri zdravljenju tumorjev in ostalih stanj, ki zahtevajo odstranitev ali uniäśenje celic
US20070237780A1 (en) * 2006-03-10 2007-10-11 Paul Averback Method of preventing or reducing the risk or incidence of cancer
US8019435B2 (en) 2006-05-02 2011-09-13 Boston Scientific Scimed, Inc. Control of arterial smooth muscle tone
US20080027005A1 (en) * 2006-07-31 2008-01-31 Paul Averback Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
ES2560006T3 (es) 2006-10-18 2016-02-17 Vessix Vascular, Inc. Inducción de efectos de temperatura deseables sobre tejido corporal
EP2076194B1 (en) 2006-10-18 2013-04-24 Vessix Vascular, Inc. System for inducing desirable temperature effects on body tissue
JP5312337B2 (ja) 2006-10-18 2013-10-09 べシックス・バスキュラー・インコーポレイテッド 標的組織の選択的な処置のための調節されたｒｆエネルギーおよび電気的な組織の特徴付け
AU2009314133B2 (en) 2008-11-17 2015-12-10 Vessix Vascular, Inc. Selective accumulation of energy with or without knowledge of tissue topography
US8703138B2 (en) 2009-04-13 2014-04-22 The Feinstein Institute For Medical Research Treatment of inflammatory diseases by inhibiting cold-inducible RNA-binding protein (CIRP)
KR20130108067A (ko) 2010-04-09 2013-10-02 베식스 바스큘라 인코포레이티드 조직 치료를 위한 발전 및 제어 장치
US9192790B2 (en) 2010-04-14 2015-11-24 Boston Scientific Scimed, Inc. Focused ultrasonic renal denervation
US8473067B2 (en) 2010-06-11 2013-06-25 Boston Scientific Scimed, Inc. Renal denervation and stimulation employing wireless vascular energy transfer arrangement
US9358365B2 (en) 2010-07-30 2016-06-07 Boston Scientific Scimed, Inc. Precision electrode movement control for renal nerve ablation
US9463062B2 (en) 2010-07-30 2016-10-11 Boston Scientific Scimed, Inc. Cooled conductive balloon RF catheter for renal nerve ablation
US9408661B2 (en) 2010-07-30 2016-08-09 Patrick A. Haverkost RF electrodes on multiple flexible wires for renal nerve ablation
US9155589B2 (en) 2010-07-30 2015-10-13 Boston Scientific Scimed, Inc. Sequential activation RF electrode set for renal nerve ablation
US9084609B2 (en) 2010-07-30 2015-07-21 Boston Scientific Scime, Inc. Spiral balloon catheter for renal nerve ablation
US8974451B2 (en) 2010-10-25 2015-03-10 Boston Scientific Scimed, Inc. Renal nerve ablation using conductive fluid jet and RF energy
US9220558B2 (en) 2010-10-27 2015-12-29 Boston Scientific Scimed, Inc. RF renal denervation catheter with multiple independent electrodes
US9028485B2 (en) 2010-11-15 2015-05-12 Boston Scientific Scimed, Inc. Self-expanding cooling electrode for renal nerve ablation
US9089350B2 (en) 2010-11-16 2015-07-28 Boston Scientific Scimed, Inc. Renal denervation catheter with RF electrode and integral contrast dye injection arrangement
US9668811B2 (en) 2010-11-16 2017-06-06 Boston Scientific Scimed, Inc. Minimally invasive access for renal nerve ablation
US9326751B2 (en) 2010-11-17 2016-05-03 Boston Scientific Scimed, Inc. Catheter guidance of external energy for renal denervation
US9060761B2 (en) 2010-11-18 2015-06-23 Boston Scientific Scime, Inc. Catheter-focused magnetic field induced renal nerve ablation
US9023034B2 (en) 2010-11-22 2015-05-05 Boston Scientific Scimed, Inc. Renal ablation electrode with force-activatable conduction apparatus
US9192435B2 (en) 2010-11-22 2015-11-24 Boston Scientific Scimed, Inc. Renal denervation catheter with cooled RF electrode
US20120157993A1 (en) 2010-12-15 2012-06-21 Jenson Mark L Bipolar Off-Wall Electrode Device for Renal Nerve Ablation
WO2012100095A1 (en) 2011-01-19 2012-07-26 Boston Scientific Scimed, Inc. Guide-compatible large-electrode catheter for renal nerve ablation with reduced arterial injury
AU2012283908B2 (en) 2011-07-20 2017-02-16 Boston Scientific Scimed, Inc. Percutaneous devices and methods to visualize, target and ablate nerves
US9186209B2 (en) 2011-07-22 2015-11-17 Boston Scientific Scimed, Inc. Nerve modulation system having helical guide
EP2765942B1 (en) 2011-10-10 2016-02-24 Boston Scientific Scimed, Inc. Medical devices including ablation electrodes
US9420955B2 (en) 2011-10-11 2016-08-23 Boston Scientific Scimed, Inc. Intravascular temperature monitoring system and method
US10085799B2 (en) 2011-10-11 2018-10-02 Boston Scientific Scimed, Inc. Off-wall electrode device and methods for nerve modulation
US9364284B2 (en) 2011-10-12 2016-06-14 Boston Scientific Scimed, Inc. Method of making an off-wall spacer cage
WO2013059202A1 (en) 2011-10-18 2013-04-25 Boston Scientific Scimed, Inc. Integrated crossing balloon catheter
WO2013058962A1 (en) 2011-10-18 2013-04-25 Boston Scientific Scimed, Inc. Deflectable medical devices
US8951251B2 (en) 2011-11-08 2015-02-10 Boston Scientific Scimed, Inc. Ostial renal nerve ablation
EP2779929A1 (en) 2011-11-15 2014-09-24 Boston Scientific Scimed, Inc. Device and methods for renal nerve modulation monitoring
US9119632B2 (en) 2011-11-21 2015-09-01 Boston Scientific Scimed, Inc. Deflectable renal nerve ablation catheter
US9265969B2 (en) 2011-12-21 2016-02-23 Cardiac Pacemakers, Inc. Methods for modulating cell function
CA2859989C (en) 2011-12-23 2020-03-24 Vessix Vascular, Inc. Methods and apparatuses for remodeling tissue of or adjacent to a body passage
CN104135958B (zh) 2011-12-28 2017-05-03 波士顿科学西美德公司 用有聚合物消融元件的新消融导管调变神经的装置和方法
US9050106B2 (en) 2011-12-29 2015-06-09 Boston Scientific Scimed, Inc. Off-wall electrode device and methods for nerve modulation
WO2013169927A1 (en) 2012-05-08 2013-11-14 Boston Scientific Scimed, Inc. Renal nerve modulation devices
CN104540465A (zh) 2012-08-24 2015-04-22 波士顿科学西美德公司 带有含单独微孔隙区域的球囊的血管内导管
CN104780859B (zh) 2012-09-17 2017-07-25 波士顿科学西美德公司 用于肾神经调节的自定位电极系统及方法
US10398464B2 (en) 2012-09-21 2019-09-03 Boston Scientific Scimed, Inc. System for nerve modulation and innocuous thermal gradient nerve block
US10549127B2 (en) 2012-09-21 2020-02-04 Boston Scientific Scimed, Inc. Self-cooling ultrasound ablation catheter
US10835305B2 (en) 2012-10-10 2020-11-17 Boston Scientific Scimed, Inc. Renal nerve modulation devices and methods
US9956033B2 (en) 2013-03-11 2018-05-01 Boston Scientific Scimed, Inc. Medical devices for modulating nerves
WO2014143571A1 (en) 2013-03-11 2014-09-18 Boston Scientific Scimed, Inc. Medical devices for modulating nerves
US9808311B2 (en) 2013-03-13 2017-11-07 Boston Scientific Scimed, Inc. Deflectable medical devices
WO2014149690A2 (en) 2013-03-15 2014-09-25 Boston Scientific Scimed, Inc. Medical devices and methods for treatment of hypertension that utilize impedance compensation
WO2014150553A1 (en) 2013-03-15 2014-09-25 Boston Scientific Scimed, Inc. Methods and apparatuses for remodeling tissue of or adjacent to a body passage
US10265122B2 (en) 2013-03-15 2019-04-23 Boston Scientific Scimed, Inc. Nerve ablation devices and related methods of use
JP2016524949A (ja) 2013-06-21 2016-08-22 ボストン サイエンティフィック サイムド，インコーポレイテッドＢｏｓｔｏｎ Ｓｃｉｅｎｔｉｆｉｃ Ｓｃｉｍｅｄ，Ｉｎｃ． 回転可能シャフトを有する腎神経アブレーション用医療装置
EP3010437A1 (en) 2013-06-21 2016-04-27 Boston Scientific Scimed, Inc. Renal denervation balloon catheter with ride along electrode support
US9707036B2 (en) 2013-06-25 2017-07-18 Boston Scientific Scimed, Inc. Devices and methods for nerve modulation using localized indifferent electrodes
JP6204579B2 (ja) 2013-07-01 2017-09-27 ボストン サイエンティフィック サイムド，インコーポレイテッドＢｏｓｔｏｎ Ｓｃｉｅｎｔｉｆｉｃ Ｓｃｉｍｅｄ，Ｉｎｃ． 腎神経アブレーション用医療器具
US10660698B2 (en) 2013-07-11 2020-05-26 Boston Scientific Scimed, Inc. Devices and methods for nerve modulation
US10413357B2 (en) 2013-07-11 2019-09-17 Boston Scientific Scimed, Inc. Medical device with stretchable electrode assemblies
US9925001B2 (en) 2013-07-19 2018-03-27 Boston Scientific Scimed, Inc. Spiral bipolar electrode renal denervation balloon
JP2016527959A (ja) 2013-07-22 2016-09-15 ボストン サイエンティフィック サイムド，インコーポレイテッドＢｏｓｔｏｎ Ｓｃｉｅｎｔｉｆｉｃ Ｓｃｉｍｅｄ，Ｉｎｃ． 腎神経アブレーション用医療器具
CN105392435B (zh) 2013-07-22 2018-11-09 波士顿科学国际有限公司 具有扭绞球囊的肾神经消融导管
EP3035879A1 (en) 2013-08-22 2016-06-29 Boston Scientific Scimed, Inc. Flexible circuit having improved adhesion to a renal nerve modulation balloon
CN105555218B (zh) 2013-09-04 2019-01-15 波士顿科学国际有限公司 具有冲洗和冷却能力的射频(rf)球囊导管
JP6392348B2 (ja) 2013-09-13 2018-09-19 ボストン サイエンティフィック サイムド，インコーポレイテッドＢｏｓｔｏｎ Ｓｃｉｅｎｔｉｆｉｃ Ｓｃｉｍｅｄ，Ｉｎｃ． 蒸着されたカバー層を有するアブレーション用医療デバイス及びその製造方法
EP3049438B1 (en) 2013-09-24 2018-07-25 The Feinstein Institute for Medical Research Peptides inhibiting cold-inducible rna binding protein activity
US9687166B2 (en) 2013-10-14 2017-06-27 Boston Scientific Scimed, Inc. High resolution cardiac mapping electrode array catheter
US11246654B2 (en) 2013-10-14 2022-02-15 Boston Scientific Scimed, Inc. Flexible renal nerve ablation devices and related methods of use and manufacture
US9770606B2 (en) 2013-10-15 2017-09-26 Boston Scientific Scimed, Inc. Ultrasound ablation catheter with cooling infusion and centering basket
EP3057520A1 (en) 2013-10-15 2016-08-24 Boston Scientific Scimed, Inc. Medical device balloon
JP6259099B2 (ja) 2013-10-18 2018-01-10 ボストン サイエンティフィック サイムド，インコーポレイテッドＢｏｓｔｏｎ Ｓｃｉｅｎｔｉｆｉｃ Ｓｃｉｍｅｄ，Ｉｎｃ． 可撓性を備える導電性ワイヤを備えるバルーン・カテーテル、並びに関連する使用および製造方法
EP3060153A1 (en) 2013-10-25 2016-08-31 Boston Scientific Scimed, Inc. Embedded thermocouple in denervation flex circuit
JP6382989B2 (ja) 2014-01-06 2018-08-29 ボストン サイエンティフィック サイムド，インコーポレイテッドＢｏｓｔｏｎ Ｓｃｉｅｎｔｉｆｉｃ Ｓｃｉｍｅｄ，Ｉｎｃ． 耐引き裂き性フレキシブル回路アセンブリを備える医療デバイス
JP6325121B2 (ja) 2014-02-04 2018-05-16 ボストン サイエンティフィック サイムド，インコーポレイテッドＢｏｓｔｏｎ Ｓｃｉｅｎｔｉｆｉｃ Ｓｃｉｍｅｄ，Ｉｎｃ． 双極電極上の温度センサの代替配置
US11000679B2 (en) 2014-02-04 2021-05-11 Boston Scientific Scimed, Inc. Balloon protection and rewrapping devices and related methods of use
US20160215031A1 (en) * 2015-01-27 2016-07-28 Nymox Pharnaceutical Corporation Method of treating disorders requiring destruction or removal of cells
US10078207B2 (en) 2015-03-18 2018-09-18 Endochoice, Inc. Systems and methods for image magnification using relative movement between an image sensor and a lens assembly
US20160361380A1 (en) 2015-06-12 2016-12-15 Nymox Corporation Combination compositions for treating disorders requiring removal or destruction of unwanted cellular proliferations
CA3029064A1 (en) * 2015-06-29 2017-01-05 The University Of British Columbia Mammalian glucosidase inhibitors, methods for their use and pharmaceutical compositions thereof
US11628202B2 (en) * 2015-07-24 2023-04-18 Nymox Corporation Methods of reducing the need for surgery in patients suffering from benign prostatic hyperplasia
US10183058B2 (en) * 2016-06-17 2019-01-22 Nymox Corporation Method of preventing or reducing the progression of prostate cancer
US10172910B2 (en) 2016-07-28 2019-01-08 Nymox Corporation Method of preventing or reducing the incidence of acute urinary retention
US10532081B2 (en) 2016-09-07 2020-01-14 Nymox Corporation Method of ameliorating or preventing the worsening or the progression of symptoms of BPH
US10335453B2 (en) 2017-03-01 2019-07-02 Nymox Corporation Compositions and methods for improving sexual function
US10835538B2 (en) 2018-03-28 2020-11-17 Nymox Corporation Method of treating benign prostatic hyperlasia with antibiotics
US20200061150A1 (en) * 2018-08-23 2020-02-27 Nymox Corporation Method of inducing selective prostate glandular pharmaco-ablation with sparing of nerves and preservation of sexual function
US20200360466A1 (en) 2019-05-13 2020-11-19 Nymox Corporation Method of improving lower urinary tract symptoms
US11278588B2 (en) 2019-05-13 2022-03-22 Nymox Corporation Method of treating lower urinary tract symptoms with fexapotide triflutate
US11298400B2 (en) 2019-05-13 2022-04-12 Nymox Corporation Method of enhancing the therapeutic efficacy of fexapotide triflutate in treating LUTS
US11331374B2 (en) 2019-07-31 2022-05-17 Nymox Corporation Focal treatment of prostate cancer
US11231421B2 (en) 2019-07-31 2022-01-25 Nymox Corporation Methods of treating multifocal cancer

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US594863A (en) * 1897-12-07 Otto p
US5169933A (en) * 1988-08-15 1992-12-08 Neorx Corporation Covalently-linked complexes and methods for enhanced cytotoxicity and imaging
US5948634A (en) 1988-12-21 1999-09-07 The General Hospital Coporation Neural thread protein gene expression and detection of alzheimer's disease
ES2094733T3 (es) * 1988-12-21 1997-02-01 Gen Hospital Corp Deteccion de enfermedades o disfunciones neurologicas.
JPH06256387A (ja) 1991-06-14 1994-09-13 Suetsuna Yoko 新規なペプチド、その製法およびそれを有効成分とする 血圧降下剤
PT1564293E (pt) 1993-04-20 2008-12-02 Gen Hospital Corp Expressão génica de proteínas de filamento neural e detecção de doença de alzheimer
FR2757486B1 (fr) 1996-12-24 1999-03-26 Sanofi Sa Receptacle de conditionnement de deux produits pouvant s'ecouler et maintenus separes avant d'etre melanges pour utilisation
EP0975651A4 (en) 1997-02-26 2005-03-09 Gen Hospital Corp TRANSGENIC ANIMALS AND CELL LINES FOR THE SCREENING OF MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF ALZHEIMER'S DISEASE
US6238667B1 (en) * 1997-09-19 2001-05-29 Heinz Kohler Method of affinity cross-linking biologically active immunogenic peptides to antibodies
CA2335986A1 (en) * 1998-06-26 2000-01-06 Simeng Suy Use of tempo and tempo derivatives for inducing cell death
WO2000018426A1 (fr) * 1998-09-30 2000-04-06 The Institute Of Physical And Chemical Research Inducteurs d'apoptose
EP1135494A2 (en) * 1998-12-11 2001-09-26 Incyte Pharmaceuticals, Inc. Neuron-associated proteins
IL144228A0 (en) * 1999-01-11 2002-05-23 Leadd Bv Use of apoptosis inducing agents in the treatment of (auto) immune diseases
WO2000055198A1 (en) 1999-03-12 2000-09-21 Human Genome Sciences, Inc. 50 human secreted proteins
JP2002543764A (ja) 1999-03-19 2002-12-24 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ４６個のヒト分泌タンパク質
AU3765500A (en) 1999-03-26 2000-10-16 Human Genome Sciences, Inc. 50 human secreted proteins
AU3769700A (en) 1999-03-26 2000-10-16 Human Genome Sciences, Inc. 45 human secreted proteins
EP1171462A2 (en) 1999-03-26 2002-01-16 Human Genome Sciences, Inc. 49 human secreted proteins
MXPA02004934A (es) 1999-11-16 2004-08-12 Unilever Nv Composiciones cosmeticas conteniendo extracto de anis y retinoides.
WO2001040521A2 (en) 1999-11-30 2001-06-07 Curagen Corporation Nucleic acids containing single nucleotide polymorphisms and methods of use thereof
CN1300779A (zh) 1999-12-22 2001-06-27 上海博德基因开发有限公司 一种新的多肽－人神经元线蛋白17和编码这种多肽的多核苷酸
CN1300783A (zh) 1999-12-23 2001-06-27 上海生元基因开发有限公司 新的人神经元线蛋白及其编码序列
AU2001271455A1 (en) 2000-06-26 2002-01-08 Millennium Pharmaceuticals, Inc. A human calcium channel protein and uses thereof
US6783969B1 (en) 2001-03-05 2004-08-31 Nuvelo, Inc. Cathepsin V-like polypeptides
ATE300951T1 (de) * 2001-05-16 2005-08-15 Nymox Corp Prävention des zelltodes durch verwendung der segmente der neurofilamentproteine
EP1390403B1 (en) 2001-05-25 2007-01-03 Nymox Corporation Peptides derived from neural thread proteins and their medical use
DE60218179T2 (de) * 2001-07-19 2007-11-22 Nymox Corp., Saint-Laurent Peptide zur behandlung von tumoren und anderen bedingungen, die die entfernung oder zerstörung von zellen erfordern
US7317077B2 (en) * 2001-11-16 2008-01-08 Nymox Pharmaceutical Corporation Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells

Also Published As

Publication number Publication date
CA2467053A1 (en) 2003-05-30
JP5357196B2 (ja) 2013-12-04
BRPI0213786B1 (pt) 2019-01-02
CN1589279A (zh) 2005-03-02
KR20120123573A (ko) 2012-11-08
CA2467053C (en) 2013-05-07
US20030166569A1 (en) 2003-09-04
US7745572B2 (en) 2010-06-29
ATE333467T1 (de) 2006-08-15
US20090286742A1 (en) 2009-11-19
NZ532721A (en) 2007-05-31
IL161591A0 (en) 2004-09-27
KR101375026B1 (ko) 2014-03-17
JP4717349B2 (ja) 2011-07-06
WO2003044053A2 (en) 2003-05-30
EP1442058A2 (en) 2004-08-04
ES2269775T3 (es) 2007-04-01
CN100509846C (zh) 2009-07-08
WO2003044053A3 (en) 2003-12-11
IL161591A (en) 2010-02-17
US8569446B2 (en) 2013-10-29
DK1442058T3 (da) 2006-12-04
DE60213274D1 (de) 2006-08-31
DE60213274T2 (de) 2007-10-31
US20130040900A1 (en) 2013-02-14
US20050032704A1 (en) 2005-02-10
EA200400632A1 (ru) 2004-10-28
CY1107578T1 (el) 2013-03-13
KR20050044471A (ko) 2005-05-12
JP2005521383A (ja) 2005-07-21
JP2011135876A (ja) 2011-07-14
PL207591B1 (pl) 2011-01-31
KR20140044399A (ko) 2014-04-14
US20090022743A1 (en) 2009-01-22
PT1442058E (pt) 2006-12-29
NO20041844L (no) 2004-07-06
AU2002342463A1 (en) 2003-06-10
BR0213786A (pt) 2004-11-09
PL370891A1 (en) 2005-05-30
US7317077B2 (en) 2008-01-08
US8293703B2 (en) 2012-10-23
EP1442058B1 (en) 2006-07-19
AU2002342463B2 (en) 2008-09-04
EA007203B1 (ru) 2006-08-25
MXPA04004489A (es) 2004-11-29
NO332842B1 (no) 2013-01-21
US7408021B2 (en) 2008-08-05
ZA200403624B (en) 2005-12-28
KR20110003552A (ko) 2011-01-12

Similar Documents

Publication Publication Date Title
BRPI0213786B8 (pt) peptídeos efetivos no tratamento de tumores e outras condições que requerem a remoção ou destruição de células
WO2003008443A3 (en) Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
CY1111120T1 (el) Πεπτιδια που παραγονται απο πρωτεϊνες νευρικων ινων και η ιατρικη τους χρηση
CY1109650T1 (el) Χρηση νευρικων νηματικων πρωτεϊνων για την αντιμετωπιση νεοπλασιων
ATE326239T1 (de) Verfahren zur behandlung von ig-e assozierten krankheiten und zusammensetzungen zur verwendung in diesen verfahren
ATE275411T1 (de) Verwendung von phyllanthus zur behandlung von chronisch entzündlichen und fibrotischen prozessen
EP1714979A3 (en) Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
ATE291434T1 (de) Verwendung von angiotensin zur behandlung von krebsmetastasierung
EP1847550A3 (en) Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
FR2831447B1 (fr) Absolues de bulbes d'allium sativum et utilisations a titre therapeutique ou cosmetique
NO20040221L (no) Peptider til fjerning eller destruksjon av celler

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 02/01/2019, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 18/11/2002 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 18/11/2022